Extract
COPD is one of the leading causes of mortality worldwide [1]. Pulmonary hypertension has been associated with reduced survival among individuals with COPD [2] and is an independent risk factor for mortality following acute exacerbations of COPD (AECOPD) [3]. Measurement of the pulmonary artery to aorta (PA:A) ratio by computed tomography (CT) and assessment of pulmonary artery enlargement (PA:A >1) outperforms echocardiography in identifying pulmonary hypertension in severe COPD [4], and pulmonary artery enlargement has been independently associated with risk for total and severe AECOPD in two large prospective COPD cohorts [5].
Abstract
Pulmonary artery enlargement on chest CT imaging is independently associated with all-cause mortality in moderate–severe COPD, after adjustment for other known risk factors for COPD mortality and cardiovascular disease http://bit.ly/2rdYOR1
Acknowledgments
The authors acknowledge the COPDGene Core Teams and COPDGene Investigators. A complete list of these personnel is available at COPDGene.org.
Footnotes
Author contributions: D.C. LaFon, M.T. Dransfield and J.M. Wells all provided substantial contributions to the conception and design of the work as well as the acquisition, analysis and interpretation of data for the work. D.C. LaFon, S.P. Bhatt, M.T. Dransfield and J.M. Wells drafted the work and all authors revised the manuscript critically for important intellectual content and gave final approval of the version to be published. D.C. LaFon and J.M. Wells agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Support statement: This work was supported by grants from the National Institutes of Health (NIH): 5T32HL105346-9 (to D.C. LaFon), K08HL123940 (to J.M. Wells). The Genetic Epidemiology of COPD Program is supported by National Institutes of Health Grants U01 HL089897 and U01 HL089856. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: D.C. LaFon reports grants from NIH (5T32HL105346-9), during the conduct of the study.
Conflict of interest: S.P. Bhatt reports grants from NIH (K23HL133438), during the conduct of the study; contract for research from ProterixBio, personal fees for advisory board work from Sunovion and GlaxoSmithKline, outside the submitted work.
Conflict of interest: W.W. Labaki has nothing to disclose.
Conflict of interest: F.N. Rahaghi has nothing to disclose.
Conflict of interest: M. Moll has nothing to disclose.
Conflict of interest: R.P. Bowler has nothing to disclose.
Conflict of interest: E.A. Regan has nothing to disclose.
Conflict of interest: B.J. Make reports funding from the NHLBI for the COPDGene study; grants and medical advisory board work from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Sunovian; personal fees for data monitoring board work from Spiration and Shire/Baxalta; CME personal fees from WebMD, National Jewish Health, American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, SPIRE Learning, Ultimate Medical Academy, Catamount Medical, Eastern Pulmonary Society, Catamount Medical Communications Medscape, Eastern VA Medical Center, Academy Continued Healthcare Learning, and Mt. Sinai Medical Center; royalties from Up-To-Date; medical advisory board work from Novartis, Phillips, Third Pole, Science 24/7 and Vernoa; grants from Pearl; outside the submitted work.
Conflict of interest: J.D. Crapo has nothing to disclose.
Conflict of interest: R. San Jose Estepar reports grants from NIH/NHLBI, during the conduct of the study; grants from NIH/NHLBI, personal fees from Toshiba, Boehringer Ingelheim and Eolo Medical, outside the submitted work; and is a founder and co-owner of Quantitative Imaging Solutions, which is a company that provides image based consulting and develops software to enable data sharing.
Conflict of interest: A.A. Diaz reports grants from National Institutes of Health (R01-HL133137), Minority Faculty Development Career Award from Brigham and Women's Hospital, during the conduct of the study.
Conflict of interest: E.K. Silverman reports grants from NIH, during the conduct of the study; grants and travel support from GlaxoSmithKline, outside the submitted work.
Conflict of interest: M.K. Han reports grants from NIH, during the conduct of the study; personal fees from GSK, BI, Mylan and AstraZeneca, research support from Novartis and Sunovion, outside the submitted work.
Conflict of interest: B. Hobbs has nothing to disclose.
Conflict of interest: M.H. Cho reports grants from NIH, during the conduct of the study; grants from GSK, personal fees from Genentech, outside the submitted work.
Conflict of interest: G.R. Washko has nothing to disclose.
Conflict of interest: M.T. Dransfield reports grants from NIH, during the conduct of the study; grants from Department of Defense, personal fees for consultancy from and contracted clinical trials for Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Boston Scientific and PneumRx/BTG, contracted clinical trials for Novartis, Yungjin and Pulmonx, personal fees for consultancy from Genentech, Quark Pharmaceuticals and Mereo, grants from NIH and American Lung Association, outside the submitted work.
Conflict of interest: J.M. Wells reports grants from NIH/NHLBI (K08 HL123940), during the conduct of the study; grants from NIH/NCATS (UH3 TR002450) and Bayer, grants and advisory board work from GSK and Mereo BioPharma, advisory board work from Boehringer Ingelheim, endpoint adjudication from Quintiles and PRA, outside the submitted work.
- Received September 6, 2019.
- Accepted October 23, 2019.
- Copyright ©ERS 2020
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org